Clinical Trial Update: LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for levosimendan (LEVEL-2) aimed at improving exercise limitation in patients with pulmonary hypertension associated with heart fa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Tenax Therapeutics, Inc. | Conditions: Pulmonary Hypertension Associated With HFpEF | Phase 3 | Status: RECRUITING